Press coverage about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aptose Biosciences earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0033770096304 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts have recently issued reports on the company. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. HC Wainwright set a $4.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Friday, November 17th. Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, Roth Capital reissued a “buy” rating and set a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Aptose Biosciences has an average rating of “Hold” and an average target price of $5.00.

Shares of Aptose Biosciences (NASDAQ APTO) traded down $0.06 during mid-day trading on Wednesday, hitting $1.72. The company had a trading volume of 430,000 shares, compared to its average volume of 392,455. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $2.30.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Insider Buying and Selling by Quarter for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.